In selling the $7.75 million, New York-based Pavmed reached its total offering amount in the new notice, which made its first sale on Aug. 5. Pavmed did not intend for the offering to last for more than one year, and it ended up lasting for less than one week.
The offering, which required just one unnamed investor, is not being made in connection with a business combination transaction, such as a merger or acquisition, according to the filing.
Pavmed did not specify its intended use of proceeds, having previously raised $4 million in May. In April, the company received FDA 510(k) clearance for its CarpX minimally invasive carpal tunnel device.
Earlier this year, Pavmed confirmed an FDA breakthrough device designation for its Lucid Diagnostics subsidiary’s EsoGuard esophageal DNA test and entered into a clinical trial with the University of Pennsylvania to study Lucid’s EsoCheck esophageal cell collection device.